Michael S Seaman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Ave RE 204, Boston, MA 02215, USA
    Virology 367:175-86. 2007
  2. ncbi request reprint The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain
    Luis R Miranda
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    J Immunol 178:7132-8. 2007
  3. pmc LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays
    Britt Piehler
    LabKey Software, Seattle, Washington 98102, USA
    BMC Immunol 12:33. 2011
  4. pmc Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 84:1439-52. 2010
  5. pmc Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Vaccine 27:5837-45. 2009
  6. pmc Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
    Marissa B Wilck
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 201:1361-70. 2010
  7. pmc Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P O Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
  8. pmc Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys
    Lauren E Grandpre
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
    Vaccine 27:1549-56. 2009
  9. pmc Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Nat Med 16:319-23. 2010
  10. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009

Detail Information

Publications43

  1. pmc Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Ave RE 204, Boston, MA 02215, USA
    Virology 367:175-86. 2007
    ....
  2. ncbi request reprint The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain
    Luis R Miranda
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    J Immunol 178:7132-8. 2007
    ..These results suggest that structural features of the Ig molecule other than the primary sequence of the variable regions play a more prominent role in HIV neutralization than anticipated...
  3. pmc LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays
    Britt Piehler
    LabKey Software, Seattle, Washington 98102, USA
    BMC Immunol 12:33. 2011
    ..Updating all instances of such a macro with new techniques can be unwieldy and introduce non-uniformity across multi-lab teams. Using Excel also poses challenges in centrally storing, sharing and associating raw data files and results...
  4. pmc Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 84:1439-52. 2010
    ..These reference viruses can facilitate the systematic characterization of NAb responses elicited by candidate vaccine immunogens...
  5. pmc Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Vaccine 27:5837-45. 2009
    ....
  6. pmc Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
    Marissa B Wilck
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 201:1361-70. 2010
    ..We conducted a clinical trial of the safety and immunogenicity of modified vaccinia Ankara (MVA) to examine the effects of dose and route of administration...
  7. pmc Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P O Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
    ..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
  8. pmc Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys
    Lauren E Grandpre
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
    Vaccine 27:1549-56. 2009
    ..Together, these studies suggest that a multi-dose vaccine regimen utilizing up to four inoculations of MVA generates robust and durable antibody-mediated immunity comparable to that elicited by replication-competent VV...
  9. pmc Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Nat Med 16:319-23. 2010
    ..Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1...
  10. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  11. ncbi request reprint Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys
    Paula M Acierno
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA
    J Immunol 176:5338-45. 2006
    ....
  12. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
    ..These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys...
  13. pmc Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys
    Wendy W Yeh
    Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Virol 84:6018-32. 2010
    ..They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies...
  14. pmc Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys
    Aravind Basavapathruni
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 84:953-63. 2010
    ..These data show that env vaccination altered the focus of the antibody-mediated selection pressure on the evolution of envelope following SIV challenge...
  15. pmc Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus
    Edwin R Manuel
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, E CLS Room 1043, Boston, Massachusetts 02215, USA
    J Virol 83:10028-35. 2009
    ..These findings suggest that immunodomination exerted by dominant responses during SHIV infection may diminish the breadth of recall responses primed during vaccination...
  16. pmc HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
    James M Kovacs
    Division of Molecular Medicine, Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:12111-6. 2012
    ..These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development...
  17. pmc Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys
    Wendy W Yeh
    Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:7052-9. 2012
    ..These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection...
  18. pmc Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
    Norman L Letvin
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Transl Med 3:81ra36. 2011
    ..This study begins to elucidate the mechanisms of vaccine protection against immunodeficiency viruses and highlights the need to analyze these immune and genetic correlates of protection in future trials of HIV vaccine strategies...
  19. pmc Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys
    Sallie R Permar
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Virol 84:8209-18. 2010
    ....
  20. pmc Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard, Boston, MA 02114, USA Electronic address
    Cell 155:531-9. 2013
    ..These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. PAPERCLIP: ..
  21. pmc Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave RE 113, Boston, MA 02215, USA
    J Virol 79:4580-8. 2005
    ..These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination...
  22. pmc Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 201:1353-60. 2010
    ..To investigate this question, we examined the effect of immunization with modified vaccinia Ankara (MVA) on subsequent challenge with replication-competent vaccinia virus (Dryvax)...
  23. pmc Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:6829-37. 2008
    ..These studies also suggest that rAd vectors warrant further assessment as candidate subunit smallpox vaccines...
  24. pmc The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays
    Jonathan S Duke-Cohan
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Vaccine 27:1154-65. 2009
    ..Our findings have important implications both for design of new recombinant subunit vaccines as well as for methods of assaying the human antibody response utilizing recombinant proteins produced in vitro...
  25. pmc Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs
    Joseph P Nkolola
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, E CLS 1047, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 84:3270-9. 2010
    ....
  26. pmc Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 79:8878-85. 2005
    ....
  27. pmc Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens
    Sandrine L Hulot
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, Massachusetts 02215, USA
    J Virol 83:9803-12. 2009
    ....
  28. doi request reprint Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
    Dan H Barouch
    1 Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA 2 Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02139, USA
    Nature 503:224-8. 2013
    ..Our findings strongly encourage the investigation of monoclonal antibody therapy for HIV-1 in humans. ..
  29. pmc Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave RE 113, Boston, MA 02215, USA
    J Virol 79:2956-63. 2005
    ..This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1...
  30. pmc Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial
    Stephen R Walsh
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 207:1888-97. 2013
    ..Defining the safety and immunogenicity of MVA-BN in key populations is therefore important...
  31. pmc Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Infect Dis 207:248-56. 2013
    ..ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans...
  32. pmc Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines
    Shawn M Sumida
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 114:1334-42. 2004
    ..Synergistic recruitment and expansion of DCs in vivo may prove a practical strategy for overcoming this limitation and potentiating immune responses to vaccines as well as other immunotherapeutic strategies...
  33. pmc International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Vaccine 29:5203-9. 2011
    ..These data inform the clinical development of alternative serotype rAd vaccine vectors in the developing world...
  34. pmc Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys
    Andrew B Wilks
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    J Immunol 185:7097-106. 2010
    ....
  35. pmc Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses
    Stephen R Walsh
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, United States
    Vaccine 31:114-9. 2012
    ..The controls used in this study were the empty vectors (MVA and FPV)...
  36. doi request reprint Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
    Peter Hraber
    aTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico bCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts cVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland dDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    AIDS 28:163-9. 2014
    ..We performed a large cross-sectional study to determine the spectrum of neutralization potency and breadth that is seen during chronic HIV-1 infection...
  37. pmc Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes
    Geoffrey O Gillard
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Pathog 7:e1002141. 2011
    ..These results demonstrate that a defined innate memory cell population alone can provide host protection against a lethal systemic infection through viral clearance...
  38. pmc Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys
    Norman L Letvin
    Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 78:7490-7. 2004
    ....
  39. doi request reprint Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of gp41
    Jia Chen
    Division of Molecular Medicine, Boston Children s Hospital, Boston, Massachusetts, USA
    J Virol 88:1249-58. 2014
    ..These results reveal a general mechanism of HIV-1 neutralization by MPER-specific antibodies that involves interactions with viral lipids. ..
  40. pmc Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity
    Hillel Haim
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Pathog 7:e1002101. 2011
    ....
  41. doi request reprint Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope
    Craig S Pace
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 62:1-9. 2013
    ..Here, we sought to assess ibalizumab antiviral breadth and potency and to identify determinants of natural preexisting resistance...
  42. pmc Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo
    Michael S Seaman
    Department of Medicine, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 78:206-15. 2004
    ..These observations suggest that CTL-based vaccines should elicit central memory rather than effector memory T cells and illustrate the importance of monitoring the phenotype and functionality of vaccine-induced, antigen-specific CTL...
  43. pmc Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody
    Michael M Freeman
    Division of Molecular Medicine, Children s Hospital, and Department of Pediatrics, Harvard Medical School, 3 Blackfan Circle, Boston, MA 02115, USA
    Structure 18:1632-41. 2010
    ..These results could guide CD4-based immunogen design and lead to a better understanding of HIV-1 entry...